Steroid-sparing strategies for managing immune-related adverse events
Journal for ImmunoTherapy of Cancer · 2026-01 · 14 (1) · e013776
DOI: 10.1136/jitc-2025-013776 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 16.01.2026. Verfasst von Jennifer J Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Immunotherapy, Steroids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, NIA NIH HHS, NCI NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
Although immune checkpoint inhibitors (ICI) have greatly improved outcomes in several cancer types, their use is also associated with immune-related adverse events (irAEs) that can impact any organ system and lead to significant morbidity and even mortality. Current approaches to treatment of irAEs largely rely on the use of systemic corticosteroids, which can compromise antitumor immune responses and oncologic outcomes. Prolonged use of systemic corticosteroids is also associated with its own set of toxicities. Thus, there is a critical need for steroid-sparing treatment approaches for irAEs. In this article, we review the literature for alternative therapeutic approaches for irAEs, which include targeted delivery (alternate routes of administration) of steroids (eg, budesonide) as well as systemic non-steroidal strategies using other mechanisms of action, such as integrin/cytokine blockade, antibody depletion, disease-modifying antirheumatic drugs and fecal microbiota transplant, among others. Many of these approaches have shown significant promise in their ability to induce a clinical response and improve symptoms, even in the setting of steroid-refractory or steroid-dependent irAEs. These approaches are being increasingly used as primary and secondary prophylaxis in patients at high risk of irAEs. Importantly, these strategies may mitigate steroid-associated toxicities, preserve antitumor immune responses and allow continuation of ICI after development of irAEs, hence enabling the full potential of ICI against cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Washington, Seattle, Washington, USA.
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- University of Washington, Seattle, Washington, USA sbhatia@uw.edu.
Förderung
- NIAMS NIH HHS
- NIA NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- Diane Wright Endowed Fund
- Conquer Cancer Foundation
- Lynn and Daniel Lerner Endowed Chair
- National Institute on Aging
Zitieren
APA
Huang, J. J., YousefiAsl, M., Singh, N., Grivas, P., & Bhatia, S. (2026). Steroid-sparing strategies for managing immune-related adverse events. Journal for ImmunoTherapy of Cancer, 14(1), e013776. https://doi.org/10.1136/jitc-2025-013776
Vancouver
Huang JJ, YousefiAsl M, Singh N, Grivas P, Bhatia S. Steroid-sparing strategies for managing immune-related adverse events. Journal for ImmunoTherapy of Cancer. 2026;14(1):e013776. doi:10.1136/jitc-2025-013776
BibTeX
@article{Huang2026,
author = {Huang, Jennifer J and YousefiAsl, Maryam and Singh, Namrata and Grivas, Petros and Bhatia, Shailender},
title = {Steroid-sparing strategies for managing immune-related adverse events},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {1},
pages = {e013776},
doi = {10.1136/jitc-2025-013776}
}
EUVIMED